Status:

COMPLETED

The Effect of NADPH Oxidase and Creatine Supplementation on Microvascular Blood Flow Regulation

Lead Sponsor:

Florida State University

Conditions:

Endothelial Dysfunction

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

This research study seeks to determine the effects of an enzyme in the human body called NADPH oxidase (NOX) on blood flow. In addition, the study will investigate the benefits of creatine monohydrate...

Detailed Description

A double-blind cross-over placebo-controlled study design will be used to determine the extent to which NOX and creatine monohydrate supplementation influences skeletal muscle microvascular blood flow...

Eligibility Criteria

Inclusion

  • Body Mass Index: 25.0-34.9 kg/m2
  • Sedentary; sedentary status will be defined as not performing purposeful exercise training more than 20 minutes per day three a week.
  • Currently residing in Tallahassee, Florida, or the surrounding area
  • Not taking any medication(s) that interfere with metabolism.
  • Not taking any antioxidant supplementation, at least four weeks before the study.
  • Not supplementing with creatine monohydrate, at least four weeks before the study.
  • Not smoking, vaping, or chewing tobacco and willing to refrain from smoking, vaping, and chewing tobacco throughout the entire study.
  • Are not pregnant or planning on becoming pregnant

Exclusion

  • Metabolic or cardiovascular abnormalities, gastrointestinal disorders, and any condition that interferes with metabolism or oxygen delivery/transport including:
  • Diagnosed cardiovascular diseases or previous myocardial infarction.
  • Uncontrolled hypertension (resting: above 140 mmHg systolic or 90 mmHg diastolic)
  • Diabetes (Type 1 or 2)
  • Uncontrolled thyroid conditions
  • Cigarette smoking: current cigarette smoker or those who quit within the previous 6 months.
  • Participants consuming supplements or medication known to impact metabolism.
  • Participants already consuming creatine monohydrate
  • Allergies or intolerance to foods included in the standardized and high carbohydrate meal.
  • Women that are pregnant or planning on becoming pregnant
  • Weight gain or loss \> 10% of body weight during the past 6 months
  • Participants consume a vegan or vegetarian diet.
  • Non-English-speaking individuals, infants, children, teenagers, cognitively impaired adults individuals, and adults who are unable to consent will be recruited for the study.

Key Trial Info

Start Date :

August 29 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 30 2024

Estimated Enrollment :

9 Patients enrolled

Trial Details

Trial ID

NCT06018480

Start Date

August 29 2023

End Date

January 30 2024

Last Update

May 16 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Florida State University

Tallahassee, Florida, United States, 32306